Join the club for FREE to access the whole archive and other member benefits.

UNITY Biotechnologies Selects a New Senolytic Candidate


Key points from article :

Selected UBX1967 as new lead drug to treat age-related diseases of the eye.

Turns off signalling proteins that encourage cells to not activate programmed cell suicide (apoptosis).

The drug may be effective among age-related diseases not involving the eyes.

Animal toxicity testing to start in second half of 2019.

Very early days but good to have more senolytics in the pipeline

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Biotechnology company devoted to research of restoring human health